Abstract: This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate 5 receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.
Type:
Application
Filed:
March 27, 2013
Publication date:
October 3, 2013
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Abstract: Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided.
Type:
Grant
Filed:
November 6, 2008
Date of Patent:
September 10, 2013
Assignees:
Hale Biopharma Ventures LLC, Aegis Therapeutics, LLC
Inventors:
Steve Cartt, David Medeiros, Edward T. Maggio
Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.
Type:
Application
Filed:
January 26, 2011
Publication date:
July 28, 2011
Inventors:
Michael A. EVANS, Kondapavulur T. VENKATESWARA-RAO, Emily A. STEIN
Abstract: Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or V1a receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.
Type:
Grant
Filed:
February 12, 2004
Date of Patent:
August 5, 2008
Assignee:
Ferring B.V.
Inventors:
Peter Hudson, Andrzej Roman Batt, Celine Marguerite Simone Heeney, Andrew John Baxter, Michael Bryan Roe, Peter Andrew Robson
Abstract: This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ═O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ═O or ═S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants.
Type:
Application
Filed:
May 23, 2002
Publication date:
May 8, 2003
Inventors:
Doreen Mary Ashworth, Gary Robert William Pitt, Peter Hudson, Chritpoher Martyn Yea, Richard Jeremy Franklin